Printer Friendly

MYCO PHARMACEUTICALS ANNOUNCES SENIOR MANAGEMENT APPOINTMENTS; BARRY BERKOWITZ NAMED PRESIDENT AND CEO, WILLIAM TIMBERLAKE TO HEAD RESEARCH

 CAMBRIDGE, Mass., March 1 /PRNewswire/ -- Myco Pharmaceuticals, Inc. today announced three senior management appointments. Barry A. Berkowitz, Ph.D., is president and CEO. William E. Timberlake, Ph.D. has been named vice president for research, and Sean C. O'Connor, Ph.D., has been appointed director of drug discovery.
 Myco, a recently formed biotechnology company, is positioned to be a world leader in using fungi as a source of drugs and in developing enabling screening technologies based on recent advances in molecular biology and fungal genetics. The company's initial therapeutic focus is to discover and develop proprietary anti-fungal and other anti-infective drugs. In addition, the company's enabling technologies and large bank of fungal-based compounds will have application to other disease categories, and represent important licensing opportunities.
 "This core group of outstanding individuals will allow the company to rapidly build a successful drug discovery program," said Gary Anderson, M.D., chairman of Myco and managing director of Technology Leaders Management, Inc., a venture capital firm. "Barry brings over 23 years of management and research experience in the pharmaceutical and biotechnology industries from the Roche Institute of Molecular Biology, SmithKline Beckman and Magainin Sciences, Inc."
 Dr. Berkowitz commented, "Dr. Timberlake, who has gained recognition as a world leader in fungal genetics and molecular biology, will spearhead Myco's program to develop proprietary screening techniques and to identify new targets for drug discovery. Dr. O'Connor has made significant contributions to natural products research and drug discovery."
 Dr. Anderson added, "The company's in-house expertise is complemented by a Scientific Advisory Board of pre-eminent researchers and clinicians. The Scientific Advisory Board is chaired by Gerald Fink, Ph.D., who is director of the Whitehead Institute for Biomedical Research and American Cancer Society Professor of Genetics at M.I.T."
 Prior to Myco, Dr. Berkowitz was founder, CEO, president, and chairman of Magainin Sciences, Inc. From 1978-1989, he served at SmithKline Beckman in various scientific and senior executive capacities, including director of pharmacology, vice president of biological research and development, and vice president of compound acquisitions and development. Dr. Berkowitz received his B.S. from Northeastern University, and received his Ph.D. in pharmacology from the University of California, San Francisco.
 Dr. Timberlake joined Myco from the University of Georgia, where he was research professor of genetics since 1986. He was professor of plant pathology at University of California, Davis from 1981-1986. Dr. Timberlake received both his B.S. in biology and chemistry and a Ph.D. in biochemistry and botany from Syracuse University.
 Dr. O'Connor served from 1982-1992 at Bristol-Myers Squibb as Distinguished Research Fellow and was director of Screening and Biochemical Research. Previously, he held a series of research positions at Eli Lilly and Company beginning in 1966. Dr. O'Connor obtained both his B.S. in chemistry and mathematics, and a Ph.D. in organic chemistry from the National University of Ireland.
 Myco Pharmaceuticals, Inc. is engaged in the discovery and development of enabling technologies and novel pharmaceuticals derived from fungi and related microorganisms. Myco was founded in 1992 and is headquartered in Cambridge, Mass.
 -0- 3/1/93
 /CONTACT: Barry A. Berkowitz, Ph.D., president and CEO of Myco Pharmaceuticals, 617-621-7073; Lynne H. Brum of Feinstein Partners, 617-577-8110, for Myco Pharmaceuticals/


CO: Myco Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU: PER

CH -- NE007 -- 1272 03/01/93 09:41 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 1, 1993
Words:555
Previous Article:CRAY RESEARCH AGREEMENT TARGETS ENGINE-DESIGN SOFTWARE ON PARALLEL VECTOR, MPP SYSTEMS
Next Article:CYTOTHERAPEUTICS ANNOUNCES BROAD U.S. PATENT COVERING THE USE OF MULTIPLE CELL TYPES IN THERAPEUTIC IMPLANTS
Topics:


Related Articles
ALAN L. CRANE JOINS MYCO AS EXECUTIVE DIRECTOR OF BUSINESS DEVELOPMENT
RECOMBINANT BIOCATALYSIS, INC. RAISES $12.5 MILLION IN SECOND ROUND OF FINANCING; APPOINTS NEW CEO, PRESIDENT
Chiron Announces Expanded BioPharma Leadership; Kenneth W. Bair, Ph.D., Joins as Senior VP, Head of BioPharma Research.
Premier Research Group Appoints Dr.. Peter Fellner as Non-Executive Chairman.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters